Comparative Pharmacology
Head-to-head clinical analysis: CHENODIOL versus URSO 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHENODIOL versus URSO 250.
CHENODIOL vs URSO 250
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chenodiol is a bile acid that reduces cholesterol saturation in bile by suppressing hepatic synthesis of cholesterol and inhibiting intestinal absorption of cholesterol. It also expands the bile acid pool and decreases biliary cholesterol secretion, promoting dissolution of cholesterol gallstones.
Ursodeoxycholic acid (UDCA) reduces endogenous bile acid synthesis and secretion by inhibiting cholesterol absorption and decreasing bile acid hydrophobicity. It also displaces toxic endogenous bile acids from the enterohepatic circulation and exerts cytoprotective, anti-apoptotic, and immunomodulatory effects on hepatocytes and cholangiocytes.
13-15 mg/kg/day orally in 2-4 divided doses, typically starting at 250 mg twice daily, then increasing by 250 mg/day every 1-2 weeks to full dose.
13-15 mg/kg/day orally in 2-4 divided doses for primary biliary cholangitis; 300 mg twice daily for gallstone dissolution.
None Documented
None Documented
Terminal elimination half-life: 3-5 days. Clinical context: Prolonged due to enterohepatic recycling; steady-state achieved in 3-4 weeks.
Terminal elimination half-life is approximately 3.5 to 5.8 days in patients with cholestatic liver disease, reflecting extensive enterohepatic recycling; in healthy individuals, half-life may be shorter.
Primarily biliary (renal excretion minimal; <1% unchanged in urine). Fecal excretion as metabolites.
Primarily fecal excretion (biliary) as unchanged drug; minimal renal excretion (<1%). Enterohepatic circulation occurs, with small amounts eliminated in bile.
Category C
Category C
Gallstone Dissolution Agent
Gallstone Dissolution Agent